Exp Clin Endocrinol Diabetes 2021; 129(01): 43-49
DOI: 10.1055/a-0787-1382
Article

Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy

Monica Verdoia
1   Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
,
Patrizia Pergolini
2   Clinical Chemistry, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
,
Roberta Rolla
2   Clinical Chemistry, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
,
Claudia Ceccon
1   Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
,
Marina Caputo
3   Department of Diabetology, Eastern Piedmont University, Novara, Italy
,
Gianluca Aimaretti
3   Department of Diabetology, Eastern Piedmont University, Novara, Italy
,
Harry Suryapranata
4   Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands
,
Giuseppe De Luca
1   Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
› Author Affiliations

Abstract

Background Enhanced platelet reactivity represents one of the major determinants of cardiovascular risk among diabetic patients. The aim of the present study was to evaluate the impact of metformin use on platelet reactivity in diabetic patients receiving dual antiplatelet therapy (DAPT).

Methods We included diabetic patients treated with DAPT after an acute coronary syndrome or percutaneous coronary intervention. Platelet reactivity was assessed at 30–90 days by Multiple-electrode aggregometry. In an additional cohort of diabetic patients naïve to antiplatelet therapy, we assessed platelet reactivity by light transmission aggregometry, surface expression of P-selectin and plasma concentration of Thromboxane B2 (TxB2).

Results We included 219 diabetic patients, 117 (53.4%) treated with metformin. Metformin was associated with younger age (p=0.03), male gender (p=0.02), lower rate of hypertension (p=0.04), active smoker (p=0.002), previous MI (p<0.001) renal failure (p<0.001), fibrinogen (p<0.001) and C-reactive protein (p=0.04), larger use of diuretics (p=0.04) calcium antagonists (p=0.05), better glycemic control (p<0.001) and higher haemoglobin (p=0.003). The prevalence of HAPR did not significantly differ according to hypoglycemic treatment (p=0.73; adjusted OR[95%CI]=5.63[0.42-76], p=0.19). Moreover, no impact of metformin was observed for HRPR (p=0.77; adjusted OR[95%CI]=1.15[0.55-2.4], p=0.71). Among an additional cohort of 42 diabetic patients naïve to antiplatelet therapy, we confirmed no impact of metformin or insulin on aggregation.

Conclusions Our study found no apparent association in diabetic patients treated with DAPT, between the use of metformin and platelet reactivity or the rate of HPR.



Publication History

Received: 01 May 2018
Received: 10 October 2018

Accepted: 02 November 2018

Article published online:
29 November 2018

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Donahoe SM, Stewart GC, McCabe CH. et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765-775
  • 2 De Luca G, Gibson CM, Bellandi F. et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009; 207: 181-185
  • 3 De Luca G, Małek LA, Maciejewski P. et al. Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry. Atherosclerosis. 2010; 210: 516-520
  • 4 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005; 54: 2430-2435
  • 5 Wisman PP, Roest M, Asselbergs FW. et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: A systematic review and meta-analysis. J Thromb Haemost 2014; 12: 736-747
  • 6 Tantry US, Bonello L, Aradi D. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273
  • 7 Henn V, Slupsky JR, Gräfe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591
  • 8 Singla A, Antonino MJ, Bliden KP. et al. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009; 158: 784.e1-e6
  • 9 Nardin M, Verdoia M, Sartori C. et al. Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. Thromb Res 2016; 143: 45-49
  • 10 Papazafiropoulou A, Papanas N, Pappas S. et al. Effects of oral hypoglycemic agents on platelet function. J Diabetes Complications 2015; 29: 846-851
  • 11 Hong J, Zhang Y, Lai S. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36: 1304-1311
  • 12 Tremoli E, Ghiselli G, Maderna P. et al. Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis. 1982; 41: 53-60
  • 13 Genovese S, De Berardis G, Nicolucci A. et al. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. Adv Ther. 2013; 30: 190-202
  • 14 American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S1-S48
  • 15 De Luca G, Secco GG, Santagostino M. et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012; 22: 426-433
  • 16 Verdoia M, Pergolini P, Camaro C. et al. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013; 24: 411-418
  • 17 Vidali M, Rolla R, Parrella M. et al. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012; 34: 484-494
  • 18 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933
  • 19 De Luca G, Dirksen MT, Spaulding C. et al. Drug-eluting vs bare-metal stents in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012; 172: 611-621
  • 20 De Luca G, Marino P. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Am J Emerg Med 2009; 27: 683-690
  • 21 De Luca G, Smit JJ, Ernst N. et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005; 93: 820-823
  • 22 De Luca G, Verdoia M, Schaffer A. et al. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: A meta-analysis of randomized trials. J CardiovascPharmacol 2014; 63: 339-350
  • 23 Dirksen MT, Spaulding C, Kelbæk H. et al. Impact of diabetes on long-term outcome after primary angioplasty: Insights from the DESERT cooperation. Diabetes Care 2013; 36: 1020-1025
  • 24 Vazzana N, Ranalli P, Cuccurullo C. et al. Diabetes mellitus and thrombosis. Thromb. Res 2012; 129: 371-377
  • 25 Vivas D, García-Rubira JC, Bernardo E. et al. Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study (“Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo”). J Thromb Thrombolysis 2013; 35: 165-174
  • 26 Roussel R, Travert F, Pasquet B. et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899
  • 27 Gastpar H, Weissgerber PW, Enzmann F. et al. The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide. Res Exp Med (Berl) 1982; 180: 75-84
  • 28 Gregorio F, Ambrosi F, Manfrini S. et al. Poorly controlled elderly Type 2 diabetic patients: The effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999; 16: 1016-1024
  • 29 Roumie CL, Hung AM, Greevy RA. et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012; 157: 601-610
  • 30 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865
  • 31 Wang YW, He SJ, Feng X. et al. Metformin: A review of its potential indications. Drug Des Devel Ther 2017; 11: 2421-2429
  • 32 American Diabetes Association . Pharmacologic approaches to glycemic treatment. Diabetes Care 2017; 40: S64-S74
  • 33 Gin H, Freyburger G, Boisseau M. et al. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 1989; 6: 61-67
  • 34 Gonçalves LH, Silva MV, Duarte RC. et al. Acetylsalicylic acid therapy: Influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. Clin Chim Acta 2014; 429: 76-78
  • 35 Xin G, Wei Z, Ji C. et al. Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. Sci Rep 2016; 6: 36222
  • 36 Collier A, Watson HH, Patrick AW. et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1989; 15: 420-425
  • 37 Bodary PF, Vargas FB, King SA. et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 3: 2149-2153
  • 38 Suryadevara S, Ueno M, Tello-Montoliu A. et al. Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thrombosis and Haemostasis 2012; 108: 930-936
  • 39 Gupta AK, Verma AK, Kailashiya J. et al. Sitagliptin: Antiplatelet effect in diabetes and healthy volunteers. Platelets 2012; 23: 565-570
  • 40 Randriamboavonjy V, Fleming I. Insulin, Insulin Resistance, and Platelet Signaling in Diabetes. Diabetes Care. 2009; 32: 528-530